^
Association details:
| Biomarker: | MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
Excerpt:
...MET amplification after disease progression following the first-line therapy; 7....
Trial ID:
Source:
Title:
594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China
Published date:
11/27/2023
Excerpt:
The ORR of pts with de novo MET amp received savo, other METi, and chemo-based regimen as 1st-line therapy were 66.7%, 0, 20%, respectively….The real-world analysis results showed the promising clinical benefit of savo in NSCLC pts with MET alterations and the acceptable safety.
Source:
Title:
Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer
Published date:
03/21/2023
Excerpt:
We explored the efficacy and safety of crizotinib versus savolitinib in patients with METex14 skipping and MET amplification, separately….In the METex14 skipping subgroup, savolitinib did not show better survival benefit with significance than crizotinib (p > 0.05). In the MET amplification subgroup, savolitinib (median PFS = 7.1 months) demonstrated a better progression-free survival benefit than crizotinib (median PFS = 1.4 months), p = 0.05....In METex14 skipping NSCLC patients, the efficacy of savolitinib and crizotinib did not show significant difference. In MET amplification patients, savolitinib showed better efficacy than crizotinib.
DOI:
10.1111/1759-7714.14848.
